Halozyme Therapeutic (HALO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2024 | 09-2024 | 06-2024 | 03-2024 | 12-2023 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 115,850 | 154,318 | 187,864 | 164,627 | 118,370 |
| Marketable Securities | 480,224 | 511,988 | 341,166 | 298,824 | 217,630 |
| Receivables | 308,455 | 285,743 | 214,524 | 195,902 | 234,210 |
| Inventories | 141,860 | 131,412 | 159,312 | 168,541 | 127,601 |
| TOTAL | $1,085,340 | $1,126,976 | $987,797 | $873,584 | $746,424 |
| Non-Current Assets | |||||
| PPE Net | 75,035 | 74,490 | 75,000 | 78,071 | 74,944 |
| Intangibles | 818,651 | 836,413 | 854,175 | 871,937 | 889,700 |
| Other Non-Current Assets | 84,451 | 80,151 | 52,481 | 17,935 | 22,202 |
| TOTAL | $978,137 | $991,054 | $981,656 | $967,943 | $986,846 |
| Total Assets | $2,063,477 | $2,118,030 | $1,969,453 | $1,841,527 | $1,733,270 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 10,249 | 12,398 | 15,430 | 13,325 | 11,816 |
| Accrued Expenses | 128,851 | 96,417 | 117,930 | 118,314 | 100,678 |
| TOTAL | $139,100 | $108,815 | $133,360 | $131,639 | $112,494 |
| Non-Current Liabilities | |||||
| Long Term Debt | 1,505,798 | 1,504,154 | 1,502,515 | 1,500,879 | 1,499,248 |
| Other Non-Current Liabilities | 54,758 | 40,406 | 30,507 | 31,201 | 37,720 |
| TOTAL | $1,560,556 | $1,556,512 | $1,546,669 | $1,532,080 | $1,536,968 |
| Total Liabilities | $1,699,656 | $1,665,327 | $1,680,029 | $1,663,719 | $1,649,462 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 123,153 | 127,227 | 126,678 | 127,274 | 126,825 |
| Common Shares | 123 | 127 | 127 | 127 | 127 |
| Retained earnings | 359,869 | 397,629 | 260,618 | 167,373 | 90,550 |
| Other shareholders' equity | 3,829 | -6,939 | -2,068 | -1,486 | -9,278 |
| TOTAL | $363,821 | $452,703 | $289,424 | $177,808 | $83,808 |
| Total Liabilities And Equity | $2,063,477 | $2,118,030 | $1,969,453 | $1,841,527 | $1,733,270 |